N-端脑钠肽前体在慢性丙型肝炎患者的表达及意义

摘要/Abstract

摘要： 目的本文旨在探讨N-端脑钠肽前体(N-terminal pro-brain natriuretic peptide, NT-proBNP)在慢性丙型肝炎(chronic hepatitis C,CHC)患者血清中的表达及意义。方法实验组CHC患者48例,对照组健康体检人群38例。记录临床资料,空腹采血测定HCV RNA、肝功能、血脂及血糖等指标,NT-proBNP浓度检测应用ELASA方法,河北省人民医院超声科2名医师同时测定心脏超声。结果实验组NT-proBNP水平显著高于对照组。CHC患者NT-proBNP与左房内径(left atrial diameter, LA)、左室后壁厚度(left ventricular posterior wall thickness, LVPW)呈正相关。结论在CHC患者中检测NT-proBNP有助于评估其心血管损害。

关键词: 慢性丙型肝炎, N-端脑钠肽前体, 肝功能, 心血管疾病

张建, 郭兆霞, 苏少慧. N-端脑钠肽前体在慢性丙型肝炎患者的表达及意义[J]. 肝脏, 2018, 23(12): 1093-1095.

参考文献

[1] Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis, 2017, 21: 631-643.
[2] Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther, 2013,37: 647-652.
[3] Kontos MC, Lanfear DE, Gosch K, et al. Prognostic Value of Serial N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients With Acute Myocardial Infarction. Am J Cardiol,2017,120: 181-185.
[4] Oremus M, McKelvie R, Don-Wauchope A,et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev, 2014,19: 413-419.
[5] Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation, 2009,120: 2177-2187.
[6] Muthukumar S, Sadacharan D, Ravikumar K, et al. A prospective study on cardiovascular dysfunction in patients with hyperthyroidism and its reversal after surgical cure. World J Surg, 2016, 40: 622-628.
[7] Omura T, Yoshiyama M, Hayashi T, et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res, 2005,96: 148-150.
[8] Poller W, Kaya Z, Muche M,et al. High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection. Clin Res Cardiol, 2017, 106: 551-556.
[9] Demir C, Demir M. Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance. Int J Clin Exp Med, 2014, 7: 2314-2318.
[10] 肖静,邹菁花,陈万. 血浆N末端B型利钠肽原水平评估肝硬化患者心功能改变及其与肝功能的关系.中华肝脏病杂志,2014, 22: 822-825.
[11] Okada K, Furusyo N, Ogawa E, et al. Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide.Endocrine, 2013,43: 200-205.

[1]	徐晓鸾, 孟繁坤, 郑颖, 孙丽娟, 李欣. ICG清除试验及肝脏弹性值在肝癌术前的应用研究[J]. 肝脏, 2020, 25(3): 264-266.
[2]	王家欢, 李震. 对比经皮射频消融术和经腹腔镜下肝切除术治疗Ⅰa期原发性肝癌的临床效果[J]. 肝脏, 2020, 25(2): 146-148.
[3]	孙慧, 仲海峰, 崔益鸿. 血液透析治疗急性药物性肝损伤的临床疗效观察[J]. 肝脏, 2020, 25(1): 69-70.
[4]	蒲长宇, 陈琦. 载药微球用于中晚期肝癌TACE术对肝功能及免疫功能的影响[J]. 肝脏, 2020, 25(1): 42-45.
[5]	刘莉, 吕蓉蓉, 陈光耀, 邹佳丽, 盛佳琪. 35例小儿肝功能衰竭PE联合CVVHDF技术治疗的疗效及预后分析[J]. 肝脏, 2019, 24(9): 1028-1031.
[6]	李瑞, 周长东. ERCP术后行LC手术时机的选择对胆囊合并胆总管结石患者肝功能、炎性反应及预后的影响[J]. 肝脏, 2019, 24(8): 938-940.
[7]	黄磊. 不同浓度吲哚菁绿在胆囊手术中的应用及其对肝功能的影响[J]. 肝脏, 2019, 24(7): 800-802.
[8]	李立新, 韩喜春, 刘松平. 熊去氧胆酸对胆总管结石合并肝生化异常患者ERCP术后肝功能的影响[J]. 肝脏, 2019, 24(7): 798-800.
[9]	刘华春, 杨根, 郑恒, 胡巧, 郭辉. 肝衰竭患者外周血Th17/Treg比率测定的价值及其与短期转归的关系[J]. 肝脏, 2019, 24(7): 790-792.
[10]	谭文敏, 赖庭文, 韩锋. IL-28B基因多态性对直接抗病毒药物治疗慢性丙型肝炎患者疗效的预测价值[J]. 肝脏, 2019, 24(7): 776-779.
[11]	范红顺, 熊志娇, 马超, 邱少霞, 沈莉华. 小剂量激素辅助双重血浆分子吸附治疗早期慢加急性肝功能衰竭的疗效及抗SLA水平观察[J]. 肝脏, 2019, 24(7): 770-773.
[12]	李永芳, 李娟, 吴慧慧, 蔡伟, 刘芸野. 胸腺肽α1对乙型肝炎相关慢加急性肝衰竭疗效分析[J]. 肝脏, 2019, 24(6): 677-679.
[13]	郭金龙, 赵旭, 纪民. 血尿酸水平与术前肝功能良好的肝癌患者化疗栓塞术后肾功能损伤风险的关系[J]. 肝脏, 2019, 24(5): 528-531.
[14]	周凡, 王冉. 慢加急性乙型肝炎肝衰竭患者血清OPN和IFI 16水平变化及临床意义[J]. 肝脏, 2019, 24(5): 534-537.
[15]	韩丹. 硫唑嘌呤联合泼尼松用于复发性自身免疫性肝病维持治疗的价值[J]. 肝脏, 2019, 24(5): 559-561.